AR036032A1 - Compuesto derivado de quinolina, composicion que lo comprende; uso del mismo en la fabricacion de medicamentos, proceso para prepararlo, y metodo para detectar y seleccionar un agente que module la actividad del mif - Google Patents
Compuesto derivado de quinolina, composicion que lo comprende; uso del mismo en la fabricacion de medicamentos, proceso para prepararlo, y metodo para detectar y seleccionar un agente que module la actividad del mifInfo
- Publication number
- AR036032A1 AR036032A1 ARP020101966A ARP020101966A AR036032A1 AR 036032 A1 AR036032 A1 AR 036032A1 AR P020101966 A ARP020101966 A AR P020101966A AR P020101966 A ARP020101966 A AR P020101966A AR 036032 A1 AR036032 A1 AR 036032A1
- Authority
- AR
- Argentina
- Prior art keywords
- substituted
- heterocycle
- hydrogen
- arylalkyl
- heterocycloalkyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 4
- 239000003795 chemical substances by application Substances 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title abstract 2
- 230000000694 effects Effects 0.000 title abstract 2
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 12
- 229910052739 hydrogen Inorganic materials 0.000 abstract 11
- 239000001257 hydrogen Substances 0.000 abstract 11
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 10
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 10
- 150000002431 hydrogen Chemical group 0.000 abstract 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 6
- 125000000217 alkyl group Chemical group 0.000 abstract 5
- 125000003118 aryl group Chemical group 0.000 abstract 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 5
- 229910052760 oxygen Inorganic materials 0.000 abstract 5
- 239000001301 oxygen Substances 0.000 abstract 5
- 125000000547 substituted alkyl group Chemical group 0.000 abstract 5
- 125000003107 substituted aryl group Chemical group 0.000 abstract 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 abstract 2
- 239000003112 inhibitor Substances 0.000 abstract 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229910052717 sulfur Chemical group 0.000 abstract 1
- 239000011593 sulfur Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Se proveen compuestos derivados de quinolina que son inhibidores del MIF útiles en el tratamiento de una variedad de trastornos, incluido el tratamiento de condiciones patológicas asociadas con la actividad del MIF. Este compuesto presenta la estructura (1) o un estereoisómero, prodroga o sal farmacéuticamente aceptable del mismo, en el cual: X es oxígeno o azufre; Y se selecciona del grupo que consiste en -NO, -NO2, -C(=O)R5, -C(=O)OR5, -C(=O)NR5R6, -NR5C(=O)R5, -NR5SO2R5 y -S(O)mR5; Z es -CH2- o -C(=O)-; m es 0, 1 o 2; n es o, 1 o 2; con la salvedad de que cuando n es 0, Z es -C(=O)-; R1 se selecciona del grupo que consiste en hidrógeno, alquilo, alquilo sustituido, arilo, arilo sustituido, arilalquilo, arilalquilo sustituido, heterociclo, heterociclo sustituido, heterocicloalquilo, heterocicloalquilo sustituido, dialquilo y R'R''N(CH2)x- donde x es 2 a 4 y donde R' y R'' son independientemente seleccionados del grupo que consiste en hidrógeno, alquilo, alquilo sustituido, arilo, arilalquilo, arilalquilo sustituido, heterociclo, heterociclo sustituido, heterocicloalquilo o heterocicloalquilo sustituido y dialquilo. R2 y R3 son independientemente seleccionados del grupo que consiste en halógeno, -R5, -OR5, -SR5 o -NR5R6; R4 es seleccionado del grupo que consiste en -CH2R7, -C(=O)NR5R6, -C(=O)OR7, -C(=O)R7 y R8; R5 y R6 son seleccionados independientemente del grupo que consiste en hidrógeno, alquilo, alquilo sustituido, arilo, arilo sustituido, arilalquilo, arilalquilo sustituido, heterociclo, heterociclo sustituido, heterocicloalquilo y heterocicloalquilo sustituido; o R5 y R6 tomados juntos con un átomo de nitrógeno al cual están unidos forman un heterociclo o heterociclo sustituido; R7 se selecciona del grupo que consiste en alquilo, alquilo sustituido, arilo, arilo sustituido, arilalquilo, arilalquilo sustituido, heterociclo, heterociclo sustituido, heterocicloalquilo y heterocicloalquilo sustituido; y R8 se selecciona del grupo que consiste en hidrógeno, alquilo, alquilo sustituido, arilo, arilo sustituido, arilalquilo, arilalquilo sustituido, heterociclo, heterociclo sustituido, heterocicloalquilo y heterocicloalquilo sustituido; con las salvedades de que: R4 no es hidrógeno ni metilo cuando R1 es fenilo, R2 y R3 son ambos hidrógeno, X es oxigeno e Y es -C(=O)OCH2CH3; R4 no es metilo cuando R1 es metilo, R2 y R3 son ambos hidrógeno, X es oxígeno e Y es -NO2; R4 no es -CH2CH2OH cuando R1 es hidrógeno o metilo, R2 es 7-cloro, R3 es hidrógeno, X es oxígeno e Y es -C(=O)OCH2CH3; y R4 no es metilo cuando R1 es metilo, R2 es hidrógeno o 7-cloro, R3 es hidrógeno, X es oxígeno e Y es -C(=O)OCH2CH3. También se proveen composiciones que contengan un inhibidor del MIF en combinación con un vehículo farmacéuticamente aceptable, así como el uso de los mismos en la fabricación de medicamentos. También se describe el proceso para la preparación de dichos compuestos y el método para detectar y seleccionar agentes moduladores del MIF.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29364201P | 2001-05-24 | 2001-05-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR036032A1 true AR036032A1 (es) | 2004-08-04 |
Family
ID=23129922
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP020101966A AR036032A1 (es) | 2001-05-24 | 2002-05-24 | Compuesto derivado de quinolina, composicion que lo comprende; uso del mismo en la fabricacion de medicamentos, proceso para prepararlo, y metodo para detectar y seleccionar un agente que module la actividad del mif |
Country Status (24)
| Country | Link |
|---|---|
| US (14) | US7105519B2 (es) |
| EP (1) | EP1389110B1 (es) |
| JP (1) | JP4346312B2 (es) |
| KR (1) | KR100896973B1 (es) |
| CN (1) | CN1523989A (es) |
| AR (1) | AR036032A1 (es) |
| AT (1) | ATE461920T1 (es) |
| AU (2) | AU2002303906B2 (es) |
| BR (1) | BR0209948A (es) |
| CA (1) | CA2447103A1 (es) |
| CZ (1) | CZ20033503A3 (es) |
| DE (1) | DE60235750D1 (es) |
| ES (1) | ES2342877T3 (es) |
| HU (1) | HUP0500101A3 (es) |
| IL (1) | IL158550A0 (es) |
| MX (1) | MXJL03000038A (es) |
| MY (1) | MY140679A (es) |
| NZ (1) | NZ529244A (es) |
| PL (1) | PL367127A1 (es) |
| PT (1) | PT1389110E (es) |
| RU (1) | RU2327695C2 (es) |
| UY (1) | UY27304A1 (es) |
| WO (1) | WO2002094203A2 (es) |
| ZA (1) | ZA200309738B (es) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2352228T3 (es) * | 2001-03-29 | 2011-02-16 | Cytokine Pharmasciences, Inc. | Procedimiento y composiciones para usar el polipéptido de cadena invariante de mhc de clase ii como receptor para el factor inhibidor de la migración de macrófagos. |
| UY27304A1 (es) * | 2001-05-24 | 2002-12-31 | Avanir Pharmaceuticals | Inhibidores del factor inhibidor de la migración de los macrófagos y métodos para su identificación |
| US20030195192A1 (en) * | 2002-04-05 | 2003-10-16 | Fortuna Haviv | Nicotinamides having antiangiogenic activity |
| US20040014744A1 (en) * | 2002-04-05 | 2004-01-22 | Fortuna Haviv | Substituted pyridines having antiangiogenic activity |
| US20060034832A1 (en) | 2002-04-26 | 2006-02-16 | Haruhide Kimura | Cell death inhibitor |
| CA2489560A1 (en) * | 2002-06-27 | 2004-01-08 | Schering Aktiengesellschaft | Substituted quinoline ccr5 receptor antagonists |
| TW200418829A (en) * | 2003-02-14 | 2004-10-01 | Avanir Pharmaceutics | Inhibitors of macrophage migration inhibitory factor and methods for identifying the same |
| TWI328009B (en) | 2003-05-21 | 2010-08-01 | Glaxo Group Ltd | Quinoline derivatives as phosphodiesterase inhibitors |
| GB0316915D0 (en) * | 2003-07-18 | 2003-08-20 | Glaxo Group Ltd | Compounds |
| US7364869B2 (en) * | 2003-07-29 | 2008-04-29 | The J. David Gladstone Institutes | Method of detecting antigen-specific T lymphocytes |
| AU2004268941A1 (en) * | 2003-08-22 | 2005-03-10 | Avanir Pharmaceuticals | Substituted naphthyridine derivatives as inhibitors of macrophage migration inhibitory factor and their use in the treatment of human diseases |
| US7592466B2 (en) | 2003-10-09 | 2009-09-22 | Abbott Laboratories | Ureas having antiangiogenic activity |
| AU2011265309B2 (en) * | 2003-11-21 | 2014-06-05 | Array Biopharma, Inc. | AKT protein kinase inhibitors |
| US20050130954A1 (en) | 2003-11-21 | 2005-06-16 | Mitchell Ian S. | AKT protein kinase inhibitors |
| JP5198848B2 (ja) * | 2004-03-29 | 2013-05-15 | ザ・フェインスタイン・インスティチュート・フォー・メディカル・リサーチ | マクロファージ遊走阻止因子阻害剤を用いる、１型糖尿病処置 |
| DE102004029573A1 (de) * | 2004-06-18 | 2005-12-29 | Gambro Lundia Ab | MIF-Adsorbent |
| AU2004323369A1 (en) * | 2004-09-17 | 2006-03-23 | Siang Beng Chng | System and method for batch conversion of RFID tag to RFID label |
| BRPI0609382A2 (pt) * | 2005-03-24 | 2010-03-30 | Avanir Pharmaceuticals | derivados da tienopiridinona como inibidores do fator inibitório de migração de macrófagos |
| ES2412858T3 (es) * | 2005-09-26 | 2013-07-12 | Avigen, Inc. | Procedimiento para tratar adicciones a drogas y conductuales |
| GB0605689D0 (en) * | 2006-03-21 | 2006-05-03 | Novartis Ag | Organic compounds |
| CA2647163C (en) * | 2006-03-24 | 2016-06-21 | The Feinstein Institute For Medical Research | Modified macrophage migration inhibitory factor inhibitors |
| CN100457895C (zh) * | 2006-05-24 | 2009-02-04 | 中国科学院生物物理研究所 | 鼠抗人巨噬细胞迁移抑制因子单克隆抗体及其应用 |
| WO2007142924A1 (en) * | 2006-05-31 | 2007-12-13 | Avigen, Inc. | Ibudilast for inhibiting macrophage migration inhibitory factor (mif) activity |
| US20070281924A1 (en) * | 2006-05-31 | 2007-12-06 | Gaeta Federico C | MIF inhibitors for treating neuropathic pain and associated syndromes |
| US7845914B2 (en) * | 2007-02-15 | 2010-12-07 | Deere & Company | Self-priming fast fill sprayer pump system |
| WO2009045543A1 (en) * | 2007-10-04 | 2009-04-09 | The Regents Of The University Of California | Treatment of conditions related to shock |
| US9643922B2 (en) | 2008-08-18 | 2017-05-09 | Yale University | MIF modulators |
| US9540322B2 (en) | 2008-08-18 | 2017-01-10 | Yale University | MIF modulators |
| EP2198879A1 (en) | 2008-12-11 | 2010-06-23 | Institut Curie | CD74 modulator agent for regulating dendritic cell migration and device for studying the motility capacity of a cell |
| US9050334B2 (en) | 2010-07-16 | 2015-06-09 | Innov88 Llc | MIF inhibitors and their uses |
| DE112010005848B4 (de) | 2010-09-06 | 2016-03-10 | Guangzhou Institutes Of Biomedicine And Health, Chinese Academy Of Sciences | Amidverbindungen |
| US9295715B2 (en) | 2010-10-02 | 2016-03-29 | The Regents Of The University Of California | Minimizing intestinal dysfunction |
| JP2014530360A (ja) | 2011-10-07 | 2014-11-17 | バクスター・ヘルスケヤー・ソシエテ・アノニムＢａｘｔｅｒ Ｈｅａｌｔｈｃａｒｅ ＳＡ | 診断マーカーとしてのｏｘＭＩＦ |
| KR20130118612A (ko) * | 2012-04-20 | 2013-10-30 | (주)네오믹스 | 신규한 아미노피리딘 유도체 및 이의 용도 |
| WO2013163758A1 (en) | 2012-05-01 | 2013-11-07 | Boyd Shelley Romayne | Methods for treating and diagnosing blinding eye diseases |
| US9549988B2 (en) | 2013-06-09 | 2017-01-24 | RJS Biologics | Pharmaceutical compounds targeted by MIF affinity-tethered moieties |
| WO2016057702A2 (en) | 2014-10-07 | 2016-04-14 | Cornell University | Methods for prognosing and preventing metastatic liver disease |
| KR20180026774A (ko) * | 2015-07-17 | 2018-03-13 | 후지필름 가부시키가이샤 | 질소-함유 헤테로시클릭 화합물 |
| WO2019141153A1 (zh) * | 2018-01-17 | 2019-07-25 | 杭州阿诺生物医药科技有限公司 | 吲哚胺2,3-双加氧酶抑制剂及其用途 |
| JP2021521173A (ja) | 2018-04-11 | 2021-08-26 | オハイオ・ステイト・イノベーション・ファウンデーション | 眼内薬物送達用の持続放出微粒子のための方法及び組成物 |
| SG11202009735QA (en) | 2018-04-13 | 2020-10-29 | Cancer Research Tech Ltd | Bcl6 inhibitors |
| SMT202300170T1 (it) | 2018-06-27 | 2023-09-06 | Bristol Myers Squibb Co | Composti naftiridinonici utili come attivatori dei linfociti t |
| KR102767739B1 (ko) | 2018-06-27 | 2025-02-12 | 브리스톨-마이어스 스큅 컴퍼니 | T 세포 활성화제로서 유용한 치환된 나프티리디논 화합물 |
| AR119821A1 (es) | 2019-08-28 | 2022-01-12 | Bristol Myers Squibb Co | Compuestos de piridopirimidinonilo sustituidos útiles como activadores de células t |
| GB201914860D0 (en) | 2019-10-14 | 2019-11-27 | Cancer Research Tech Ltd | Inhibitor compounds |
| CA3162992A1 (en) * | 2019-12-23 | 2021-07-01 | Louis S. Chupak | Substituted quinolinonyl piperazine compounds useful as t cell activators |
| KR20220119454A (ko) | 2019-12-23 | 2022-08-29 | 브리스톨-마이어스 스큅 컴퍼니 | T 세포 활성화제로서 유용한 치환된 퀴나졸리닐 화합물 |
| US12454531B2 (en) | 2019-12-23 | 2025-10-28 | Bristol-Myers Squibb Company | Substituted piperazine derivatives useful as T cell activators |
| AR120823A1 (es) | 2019-12-23 | 2022-03-23 | Bristol Myers Squibb Co | Compuestos bicíclicos sustituidos útiles como activadores de células t |
| CN113121435B (zh) * | 2021-04-20 | 2022-08-30 | 辽宁大学 | 一种2,4-二氯喹啉类化合物的合成方法 |
| CN119074725A (zh) * | 2024-09-11 | 2024-12-06 | 北京大学第一医院(北京大学第一临床医学院) | 靶向mif在制备用于治疗特应性皮炎的药物中应用 |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4324893A (en) | 1979-04-18 | 1982-04-13 | American Home Products Corporation | 4-Amino-3-carboxy or cyano-1,2-dihydro-2-oxo-1,8-naphthyridine derivatives |
| US4299814A (en) | 1979-05-25 | 1981-11-10 | Monsanto Company | Radioimmunoassay of MIF |
| US4284768A (en) * | 1980-07-02 | 1981-08-18 | American Home Products Corporation | 1,2-Dihydro-4-amino-2-oxo-3-quinoline-carboxylic acid derivatives |
| AU592749B2 (en) | 1984-02-22 | 1990-01-25 | Evans Medical Limited | Cloning of dna for protozoal antigens |
| US5700447A (en) | 1992-05-21 | 1997-12-23 | The Picowder Institute For Medical Research | Methods and materials for the diagnosis and treatment of conditions such as stroke |
| US5801200A (en) | 1984-03-19 | 1998-09-01 | The Picower Institute For Medical Research | Methods and materials for the diagnosis and treatment of conditions such as stroke |
| US5869534A (en) | 1992-05-21 | 1999-02-09 | The Picower Institute For Medical Research | Glycosylation of lipids and lipid-containing particles, and diagnostic and therapeutic methods and materials derived therefrom |
| US5733933A (en) | 1984-03-19 | 1998-03-31 | The Picower Institute For Medical Research | Methods and materials for the diagnosis and treatment of conditions such as stroke |
| US5733524A (en) | 1984-03-19 | 1998-03-31 | The Picower Institute For Medical Research | Methods and materials for the diagnosis and treatment of conditions such as stroke |
| AU592753B2 (en) | 1984-05-24 | 1990-01-25 | Ciba-Geigy Ag | Lymphokine in pure foem, novel monoclonal antibodies hybridoma cell lines, processes and applications |
| JPH0672158B2 (ja) | 1984-05-24 | 1994-09-14 | チバ−ガイギ− アクチエンゲゼルシヤフト | 精製されたヒトマクロファージ遊走阻止因子 |
| US4708937A (en) | 1984-10-15 | 1987-11-24 | Brigham & Women's Hospital | Purified migration inhibitory factor also having colony stimulating factor activity |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| GB8602626D0 (en) | 1986-02-04 | 1986-03-12 | Ciba Geigy Ag | Neurite-promoting factor |
| EP0263072B1 (en) | 1986-10-03 | 1994-03-23 | Ciba-Geigy Ag | Novel lymphokine related peptides |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| WO1990011301A1 (en) | 1989-03-17 | 1990-10-04 | Genetics Institute, Inc. | Human macrophage migration inhibitory factor |
| FI82144C (fi) | 1989-03-22 | 1991-01-10 | Wallac Oy | Foerfarande foer samtidig bestaemning av flera ligander. |
| GB8915414D0 (en) | 1989-07-05 | 1989-08-23 | Ciba Geigy | Novel cytokines |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5328990A (en) | 1991-04-26 | 1994-07-12 | The United States Of America As Represented By The Department Of Health And Human Services | Isolation of macrophage migration inhibition factor from ocular lens |
| CA2054602C (en) | 1991-10-31 | 2003-04-22 | Anthony Pawson | Method for assaying for a substance that affects an sh2-phosphorylated ligand regulatory system |
| US5624804A (en) | 1991-12-20 | 1997-04-29 | The Rockefeller University | Immunochemical detection of In vivo advanced glycosylation end products |
| US6774227B1 (en) | 1993-05-17 | 2004-08-10 | Cytokine Pharmasciences, Inc. | Therapeutic uses of factors which inhibit or neutralize MIF activity |
| US6080407A (en) | 1993-05-17 | 2000-06-27 | The Picower Institute For Medical Research | Diagnostic assays for MIF |
| CA2163211C (en) | 1993-05-17 | 2012-05-08 | Richard J. Bucala | Inhibition of migration inhibitory factor in the treatment of diseases involving cytokine-mediated toxicity |
| US5650295A (en) | 1995-06-02 | 1997-07-22 | Human Genone Sciences, Inc. | Macrophage migration inhibitory factor-3 |
| US6080408A (en) | 1994-08-22 | 2000-06-27 | Connaught Laboratories Limited | Human immunodeficiency virus type 1 nucleic acids devoid of long terminal repeats capable of encoding for non-infectious, immunogenic, retrovirus-like particles |
| SI9400363A (en) | 1994-09-19 | 1996-08-31 | Mozetic Francky Bojana | Human macrophage migration inhibitory factor of nonlymphoid origin, expression of mif in e. coli and purification of recombinant protein |
| US5955203A (en) | 1994-10-05 | 1999-09-21 | Simpson Timber Company | Resin-coated overlays for solid substrates |
| WO1996015242A2 (en) | 1994-11-16 | 1996-05-23 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Methods for inhibiting cell proliferation by inhibiting the mitogenic activity of macrophage migration inhibitory factor |
| DE19601697A1 (de) | 1996-01-18 | 1997-07-24 | Wacker Chemie Gmbh | Redispergierbare Tackifierpulver |
| US6492428B1 (en) | 2000-07-26 | 2002-12-10 | The Picower Institute For Medical Research | Compounds having MIF antagonist activity |
| US6420188B1 (en) | 1996-02-16 | 2002-07-16 | The Picower Institute For Medical Research | Screening assay for the identification of inhibitors for macrophage migration inhibitory factor |
| AU727108B2 (en) | 1996-04-18 | 2000-11-30 | Ariad Pharmaceuticals, Inc. | In vitro fluorescence polarization assay |
| US5883224A (en) | 1996-04-19 | 1999-03-16 | Cytokine Sciences, Inc. | Characterization of transfer factors and methods of use |
| US5919815A (en) * | 1996-05-22 | 1999-07-06 | Neuromedica, Inc. | Taxane compounds and compositions |
| JPH1171351A (ja) | 1997-08-29 | 1999-03-16 | Ss Pharmaceut Co Ltd | 置換キノロン誘導体及びこれを含有する医薬 |
| US6413939B1 (en) | 1997-10-31 | 2002-07-02 | The Picower Institute For Medical Research | Inducible phosphofructokinase and the Warburg effect |
| JP2002521690A (ja) | 1998-07-28 | 2002-07-16 | バイオメトリック イメージング インコーポレイテッド | 細胞運動性アッセイのための装置および方法 |
| WO2000008158A2 (en) | 1998-08-07 | 2000-02-17 | Immunex Corporation | Molecules designated ldcam |
| US6214343B1 (en) | 1999-05-24 | 2001-04-10 | Ophidian Pharmaceuticals, Inc. | Prevention and treatment of necrotizing enterocolitis |
| AU1235601A (en) * | 1999-10-29 | 2001-05-14 | Cytokine Pharmasciences, Inc. | Compounds having mif antagonist activity |
| CN1842346A (zh) | 2001-01-12 | 2006-10-04 | 塞托凯恩药物科学公司 | 由巨噬细胞迁移抑制因子调节细胞毒性淋巴细胞反应 |
| ES2352228T3 (es) | 2001-03-29 | 2011-02-16 | Cytokine Pharmasciences, Inc. | Procedimiento y composiciones para usar el polipéptido de cadena invariante de mhc de clase ii como receptor para el factor inhibidor de la migración de macrófagos. |
| UY27304A1 (es) | 2001-05-24 | 2002-12-31 | Avanir Pharmaceuticals | Inhibidores del factor inhibidor de la migración de los macrófagos y métodos para su identificación |
| CA2459224C (en) | 2001-09-03 | 2012-05-08 | Takeda Chemical Industries, Ltd. | 1,3-benzothiazinone derivatives and the use thereof |
| FR2829491B1 (fr) | 2001-09-12 | 2005-09-30 | Diverchim | Procede de preparation des hydroxy-acides gras insatures et de leurs esters, leur utilisation comme agent anti-collagenase |
| AU2002365941A1 (en) | 2001-12-05 | 2003-09-02 | North Shore-Long Island Jewish Research Institute | Methods of diagnosis, monitoring and treatment of fertility |
| US20040019921A1 (en) | 2001-12-19 | 2004-01-29 | Fingerle-Rowson Gunter R. | Non-human mammal with disrupted or modified MIF gene, and uses thereof |
| US20060034832A1 (en) | 2002-04-26 | 2006-02-16 | Haruhide Kimura | Cell death inhibitor |
| JP2006511445A (ja) | 2002-06-07 | 2006-04-06 | コーティカル・ピーティーワイ・リミテッド | マクロファージ遊走阻止因子（ｍｉｆ）のサイトカインまたは生物学的活性を阻害するナフタレン誘導体 |
| NZ537301A (en) | 2002-06-07 | 2006-06-30 | Cortical Pty Ltd | Therapeutic molecules and methods-1 |
| EA200500376A1 (ru) | 2002-09-18 | 2005-08-25 | Пфайзер Продактс Инк. | Триазольные производные в качестве ингибиторов трансформирующего фактора роста (tgf) |
| AU2003289176A1 (en) | 2002-12-05 | 2004-07-29 | Takeda Pharmaceutical Company Limited | 1,3-benzothiazinone derivatives, process for producing the same and use thereof |
| TW200418829A (en) | 2003-02-14 | 2004-10-01 | Avanir Pharmaceutics | Inhibitors of macrophage migration inhibitory factor and methods for identifying the same |
| US7361474B2 (en) | 2003-02-24 | 2008-04-22 | United States Of America As Represented By The Department Of Veterans Affairs | Serum macrophage migration inhibitory factor (MIF) as marker for prostate cancer |
| AU2004268941A1 (en) | 2003-08-22 | 2005-03-10 | Avanir Pharmaceuticals | Substituted naphthyridine derivatives as inhibitors of macrophage migration inhibitory factor and their use in the treatment of human diseases |
| BRPI0609382A2 (pt) | 2005-03-24 | 2010-03-30 | Avanir Pharmaceuticals | derivados da tienopiridinona como inibidores do fator inibitório de migração de macrófagos |
-
2002
- 2002-05-23 UY UY27304A patent/UY27304A1/es not_active Application Discontinuation
- 2002-05-23 MY MYPI20021922A patent/MY140679A/en unknown
- 2002-05-24 CN CNA02810501XA patent/CN1523989A/zh active Pending
- 2002-05-24 AR ARP020101966A patent/AR036032A1/es unknown
- 2002-05-24 NZ NZ529244A patent/NZ529244A/en unknown
- 2002-05-24 RU RU2003132534/04A patent/RU2327695C2/ru not_active IP Right Cessation
- 2002-05-24 US US10/156,650 patent/US7105519B2/en not_active Expired - Fee Related
- 2002-05-24 HU HU0500101A patent/HUP0500101A3/hu unknown
- 2002-05-24 KR KR1020037015359A patent/KR100896973B1/ko not_active Expired - Fee Related
- 2002-05-24 EP EP02731971A patent/EP1389110B1/en not_active Expired - Lifetime
- 2002-05-24 MX MXJL03000038A patent/MXJL03000038A/es active IP Right Grant
- 2002-05-24 CZ CZ20033503A patent/CZ20033503A3/cs unknown
- 2002-05-24 PT PT02731971T patent/PT1389110E/pt unknown
- 2002-05-24 BR BR0209948-9A patent/BR0209948A/pt not_active Application Discontinuation
- 2002-05-24 WO PCT/US2002/016963 patent/WO2002094203A2/en not_active Ceased
- 2002-05-24 PL PL02367127A patent/PL367127A1/xx unknown
- 2002-05-24 JP JP2002590924A patent/JP4346312B2/ja not_active Expired - Fee Related
- 2002-05-24 IL IL15855002A patent/IL158550A0/xx unknown
- 2002-05-24 ES ES02731971T patent/ES2342877T3/es not_active Expired - Lifetime
- 2002-05-24 AT AT02731971T patent/ATE461920T1/de active
- 2002-05-24 DE DE60235750T patent/DE60235750D1/de not_active Expired - Lifetime
- 2002-05-24 AU AU2002303906A patent/AU2002303906B2/en not_active Ceased
- 2002-05-24 CA CA002447103A patent/CA2447103A1/en not_active Abandoned
-
2003
- 2003-12-17 ZA ZA200309738A patent/ZA200309738B/xx unknown
-
2005
- 2005-07-15 US US11/182,360 patent/US7514225B2/en not_active Expired - Fee Related
- 2005-07-15 US US11/182,241 patent/US7732146B2/en not_active Expired - Fee Related
- 2005-11-07 US US11/268,375 patent/US7084141B2/en not_active Expired - Fee Related
-
2006
- 2006-01-31 US US11/344,938 patent/US7202248B2/en not_active Expired - Fee Related
- 2006-05-02 US US11/415,552 patent/US7235565B2/en not_active Expired - Fee Related
- 2006-05-02 US US11/415,842 patent/US7238809B2/en not_active Expired - Fee Related
- 2006-05-02 US US11/415,998 patent/US7129236B2/en not_active Expired - Fee Related
- 2006-05-02 US US11/416,165 patent/US7230106B2/en not_active Expired - Fee Related
- 2006-05-02 US US11/415,785 patent/US7192955B2/en not_active Expired - Fee Related
- 2006-05-02 US US11/416,004 patent/US7157469B2/en not_active Expired - Fee Related
- 2006-05-02 US US11/415,628 patent/US7192961B2/en not_active Expired - Fee Related
- 2006-12-07 US US11/635,319 patent/US7435737B2/en not_active Expired - Fee Related
-
2007
- 2007-03-16 US US11/687,611 patent/US7432374B2/en not_active Expired - Fee Related
- 2007-04-04 AU AU2007201493A patent/AU2007201493A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR036032A1 (es) | Compuesto derivado de quinolina, composicion que lo comprende; uso del mismo en la fabricacion de medicamentos, proceso para prepararlo, y metodo para detectar y seleccionar un agente que module la actividad del mif | |
| AR046297A1 (es) | Inhibidores de la dpp - iv metodos para prepararlos y composiciones farmaceuticas que los contienen como agente activo | |
| AR012593A1 (es) | Pirrolopiridinas sustituidas, composicion farmaceutica que las contiene, procedimiento para su preparacion y el uso de las mismas en la manufacturade un medicamento | |
| AR043190A1 (es) | Derivados de quinoleina como inhibidores del factor inhibidor de la migracion de macrofagos y metodos para su identificacion. sintesis y composiciones farmaceuticas. | |
| RU2010116253A (ru) | Производные n-гидроксилсульфонамида как новые физиологически применимые доноры нитроксила | |
| ECSP066383A (es) | Derivados de 5-fenil-4-metil-tiazol-2-il-amina como inhibidores de enzimas de cinasa fosfatidilinositol 3 (pi3) para el tratamiento de enfermedades inflamatorias de las vías respiratorias | |
| HUP0203438A2 (hu) | Foszfodiészteráz gátló hatású 5-(2-helyettesített-5-heterociklilszulfonilpirid-3-il)-dihidropirazolo[4,3-d]-pirimidin-7-on-származékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
| AR036044A1 (es) | Compuestos piranoindazoles, composiciones farmaceuticas y su uso para la manufactura de un medicamento para el tratamiento del glaucoma | |
| MXPA03011638A (es) | Nuevos derivados de 4-piperazinil indol con afinidad por el receptor 5-ht6. | |
| ECSP034642A (es) | Derivados de tetralona como agentes antitumorales | |
| RU2012146986A (ru) | Цефемовые соединения, содержащие катехольную группу | |
| BR0307409A (pt) | Compostos de hidrazida de ácido 2-furanocarboxìlico, composições farmacêuticas contendo os mesmos e uso dos mesmos para preparação de um agente preventivo ou terapêutico | |
| FR2809396B1 (fr) | Nouvelles molecules possedant une activite calcimimetique et leur mode de preparation | |
| AR019669A1 (es) | Uso de diazepinas para la preparacion de medicamentos para el tratamiento de estados patologicos o enfermedades en los cuales esta involucrado por lo menosuno de los receptores de somatostatina, diazepinas utilizadas en dicha preparacion y medicamento y composicion farmaceutica que los contienen. | |
| NO20081582L (no) | Benzamidforbindelser anvendbare som histon-deacetylaseinhibitorer | |
| MA22895A1 (fr) | 7-(2-aminoethyl) benzothiazolones. | |
| DE602004028880D1 (de) | Analoga von Apogossypol zur Verwendung in der Behandlung von Krebs | |
| ES2038172T3 (es) | Procedimiento para preparar carboxamidas heterociclicas. | |
| UY27803A1 (es) | Derivados de benzoxazina y usos de los mismos. | |
| FR2800735B1 (fr) | Nouvelles aralkyle-1,2-diamines possedant une activite calcimimetique et leur mode de preparation | |
| AR007108A1 (es) | Agentes antitumorales y antivirales alquilantes, procedimiento para su preparacion, utilizacion de los mismos para la fabricacion de un medicamento y composicion farmaceutica que contiene a dichos agentes. | |
| PE20251706A1 (es) | Compuestos de urea triciclica como inhibidores de v617f de jak2 | |
| PE20030705A1 (es) | Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades androgeno-dependientes | |
| PE20061156A1 (es) | Derivados de benzamida como agentes inhibidores del transportador de glicina | |
| PE20021018A1 (es) | DERIVADOS DE ß - CARBOLINA |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |